What's Hot
View all perspectives
TheDaoIndex KDAO2011
2 years 5 months ago
#EULAR2022 RA updated reccs w/ minor changes: start MTX+GC, reduce GC rapidly, JAKi are recc only for pts w/o risk factors for CV or malignant dz (not sure I agree with this last one if the JAKi is the best drug for the pt and there are little options avail) @rheumnow https://t.co/CXyyCi6LVI
TheDaoIndex KDAO2011
2 years 5 months ago
Overarching principles #EULAR2022 AAV Updated reccs are patient centered:
1. Best care w/shared decision making
2. Access to education on AAV
3. Screen pts for Rx side effects/comorbidities
4. Need a multidisciplinary approach w/vasculitis expertise @rheumnow https://t.co/OgE4l4np12
Robert B Chao, MD doctorRBC
2 years 5 months ago
Musculoskeletal US used by dermatologists helped increasedspecificity of PsA detection, leading to fewer false suspicions of PsA earlier diagnosis of psoriatic arthritis.
@RheumNow #EULAR2022 ABST#OP0029
Eric Dein ericdeinmd
2 years 5 months ago
After the #EULAR2022 Recommendations session, it begs the question - Do we follow it?
In Germany, the answer is sometimes
Early bDMARD or JAKi is more frequent in recent years. 1/3 of patients did not receive recommended treatment escalation after 1st csDMARD
POS0234 @Rheumnow https://t.co/0DaP5b7Htc
TheDaoIndex KDAO2011
2 years 5 months ago
Real-world data: #SLE Rx & pt willingness to take risk: 342 pts w/SLE surveyed on hypothetical Rx's based on Sx's. Pts value Sx improvement more than risks & rated most➡️least important: joint pain, rash, & fatigue, risk for infx was least impt #EULAR2022 @Rheumnow POS0086-PARE
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 Update ANCA-associated vasculitis
⭐️Last update 2016
▶️Tissue bx important!
▶️RTX for most for remission, maintenance
▶️Lower steroids (50-75 mg, decrease to 5 mg/d by 4-5 mo), can use avacopan to ⬇️
▶️ No routine PLEX
▶️Maintenance is 24-48 mo, tailor to pt
@RheumNow https://t.co/OmCne2lIIb
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 EGPA recommendations:
Organ or life-threatening? Y = CYC, N = steroid
Relapsing disease? Mepolizumab
@Rheumnow https://t.co/qh564cAhC2
TheDaoIndex KDAO2011
2 years 5 months ago
#EULAR2022 AAV Reccs summarized for induction remission for GPA/MPA @rheumnow https://t.co/Cbp72bCcik
Eric Dein ericdeinmd
2 years 5 months ago
Do you use PJP prophylaxis on patients with ANCA vasculitis on rituximab without high dose steroids?
#EULAR2022 ANCA-associated recommendations
@RheumNow
TheDaoIndex KDAO2011
2 years 5 months ago
#EULAR2022 AAV Reccs for Steroids: start prednisone 50-75 mg/d prednisone and taper to goal 5 mg/day by 4-5 months based on #PEXIVAS @rheumnow https://t.co/6gIfme4HXH
TheDaoIndex KDAO2011
2 years 5 months ago
Overarching principles of #EULAR2022 Ax Spa Updated Reccs @Rheumnow https://t.co/g6Hd9NE1vB
Dr. Rachel Tate uptoTate
2 years 5 months ago
#EULAR2022 updated ASAS-EULAR guidelines for the management of axSpA review with Dr. @sofiaramiro82 @RheumNow https://t.co/SHg4y49auA
TheDaoIndex KDAO2011
2 years 5 months ago
#EULAR2022 ASAS Updated Reccs: Treatment Algorithm @rheumnow https://t.co/YEdhrAX0lT
Dr. Rachel Tate uptoTate
2 years 5 months ago
#EULAR2022 ASAS-EULAR guidelines for axSpA with Dr. @sofiaramiro82. Below are the recommendations including b/tsDMARDs. If ASDAS > 2.1 the recommendations call for consideration for TNFi, IL17i, or JAKi. Re-evaluate after at least 12 weeks on tx and for co-morbidities. @RheumNow https://t.co/mryL3YmtzN
Dr. Rachel Tate uptoTate
2 years 5 months ago
Dr. @sofiaramiro82 important conclusion considerations from the ASAS-EULAR guidelines for axSpa. @RheumNow #EULAR2022 https://t.co/7Q3zxo7euj
Poster Hall